Detalhe da pesquisa
1.
Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.
Future Oncol
; 18(19): 2415-2431, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35583358
2.
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.
Br J Haematol
; 174(5): 692-9, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27118109
3.
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Lancet Oncol
; 12(8): 773-84, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21724462
4.
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
Clin Cancer Res
; 19(9): 2551-61, 2013 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23549871
5.
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
J Hematol Oncol
; 5: 67, 2012 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-23088650